News

Public · Published

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO announced that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Approval is based on complete response, defined as no surgery in the 12 months after treatment. The company expects ordering and shipping to begin in about 60 days.

Published:

Updated:

What happened

INOVIO announced that the FDA granted accelerated approval for VOCERYQ, a DNA-based immunotherapy, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Approval is based on complete response, defined as no surgery in the 12 months after treatment. The company expects ordering and shipping to begin in about 60 days.

Confirmed

Global impact / market context

The approval gives INOVIO a path to sell a treatment for a rare disease where patients often need surgery, potentially creating product revenue as access begins. However, accelerated approval is conditional: continued approval may depend on the company verifying and describing clinical benefit, leaving a regulatory requirement beyond the initial decision.

Analyst inference

The approval creates a path for INOVIO to begin selling the treatment, but the article gives no sales forecast or expected price. Revenue could depend on how quickly orders begin and whether the treatment is adopted; continued approval may also depend on further clinical evidence reviewed by the FDA.

Analyst inference

What to watch

  1. Watch whether VOCERYQ becomes available to order and ship in approximately 60 days, as INOVIO expects; that would mark the first step toward commercial sales. Confirmed
  2. Track INOVIO’s stated plan for a full commercial launch in the first quarter of next year; broader availability could help determine how quickly sales develop. Proposed
  3. Watch for the FDA’s required verification and description of clinical benefit, which may determine whether accelerated approval continues and how much regulatory uncertainty remains for VOCERYQ. Analyst inference

Evidence

  • Original source link unavailable